The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer(University of Tübingen), Juliane S. Walz(University Children's Hospital Tübingen)Nature CommunicationsOctober 27, 202210.1038/s41467-022-33746-3Cited by 73SaveCiteExport RISWatch citationsRelated PapersA COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity|Nature|2021|273Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer|Cancer Discovery|2021|47Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma|Blood Cancer Journal|2020|21Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy|Cancers|2021|2